Novartis to Raise $11 Billion in Bonds to Fund Acquisition of Avidity Biosciences

Mar 16, 2026 16:18 UTC

NVS, AVID, XLV, ^VIX

Short term

Novartis AG is set to issue $11 billion in bonds to finance its acquisition of biotechnology firm Avidity Biosciences Inc., marking a major corporate move in the healthcare sector. The transaction underscores Novartis’s aggressive growth strategy and could influence biotech valuations and credit market dynamics.

Novartis AG to issue $11 billion in bonds
Funding for acquisition of Avidity Biosciences Inc.
Avidity Biosciences based in San Diego, California
Deal nearing completion, with no final agreement yet
Impact expected on healthcare sector and biotech valuations
Relevant financial instruments: NVS, XLV, ^VIX

Novartis AG is preparing to issue $11 billion in bonds to secure funding for its planned acquisition of Avidity Biosciences Inc., a biotechnology company based in San Diego, California. The bond issuance reflects Novartis’s strategic commitment to expanding its presence in the biotech space through high-impact deals. The transaction, while not yet finalized, is advancing as the two companies near a definitive agreement. The move signals a significant shift in Novartis’s capital allocation, prioritizing innovation-driven growth over traditional R&D expenditures. The deal could reshape competitive dynamics within the healthcare and biotechnology sectors, particularly in rare disease and genetic therapies. Investors are likely to monitor the impact on Novartis’s credit profile and the broader healthcare ETF, XLV, amid rising market volatility reflected in the VIX index.